AWM
RCUS icon

AE Wealth Management’s Arcus Biosciences RCUS Stock Holding History

AE Wealth Management’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-24,938
Closed -$377K – 1795
2023
Q4 		$377K Buy
24,938
+2,098
+9% +$33.5K ﹤0.01% 1596
2023
Q3 		$410K Buy
+22,840
New +$459K ﹤0.01% 1485

Other funds holding RCUS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
IFA
Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

AE Wealth Management's RCUS Position: Q1 2024 in Review

AE Wealth Management sold out of Arcus Biosciences (RCUS) in Q1 2024, closing a stake of 24,938 shares — an estimated $377K sold.

AE Wealth Management first reported a position in RCUS in Q3 2023 and held it in 2 quarters. The position peaked at $410K in Q3 2023. 172 funds tracked by Wall St. Rank hold RCUS as of Q1 2024.

  • AE Wealth Management reported no remaining Arcus Biosciences position as of Q1 2024 after selling out during the quarter.
  • AE Wealth Management sold 24,938 Arcus Biosciences shares in Q1 2024, an estimated $377K.
  • AE Wealth Management first reported a position in Arcus Biosciences in Q3 2023 and held it in 2 quarters.
  • AE Wealth Management's Arcus Biosciences position peaked at $410K in Q3 2023.
  • 172 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2024.

Based on AE Wealth Management's 13F filing for Q1 2024, filed 15 May 2024.